GP Pharm SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GP Pharm SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0482
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GP Pharm SA (GP Pharm) is a biopharmaceutical company that develops and markets injectables in the areas of oncology and urology. The company provides product portfolio such as injectable dosage forms for the treatment of advanced prostate cancer; nocturnal enuresis and central diabetes insipidus; endometriosis, women fertility and precocious puberty, among others. It provides products for acromegaly and gastro esophageal variceal bleed; acute hemorrhages of the upper gastro enteric tract; colorectal cancer; ovarian, lung, pancreas and metastatic breast cancers; and for preventing uterine atony following the infant delivery through caesarean section, among others. GP Pharm is developing its pre-clinical candidates in the areas of oncology, central nervous system disorders and musculoskeletal disorders. The company also offers contract development and contract manufacturing of pharmaceutical injectables for sterile drug products. The company has a manufacturing facility at Catalonia, Barcelona, and others. GP Pharm is headquartered in Barcelona, Spain.

GP Pharm SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GP Pharm SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
GP Pharm SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GP Pharm SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 10
Licensing Agreements 11
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 11
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 12
Lee’s Pharma Enters Into Licensing Agreement With GP Pharm For Leuprolide 13
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 14
GP Pharm SA – Key Competitors 15
GP Pharm SA – Key Employees 16
GP Pharm SA – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
GP Pharm SA, Pharmaceuticals & Healthcare, Key Facts 2
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GP Pharm SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GP Pharm SA, Deals By Therapy Area, 2012 to YTD 2018 8
GP Pharm SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 10
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 11
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 12
Lee's Pharma Enters Into Licensing Agreement With GP Pharm For Leuprolide 13
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 14
GP Pharm SA, Key Competitors 15
GP Pharm SA, Key Employees 16
GP Pharm SA, Other Locations 17

List of Figures
GP Pharm SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
GP Pharm SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
GP Pharm SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[GP Pharm SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cenovus Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Cenovus Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Cenovus Energy Inc (Cenovus Energy) is an integrated energy company, which explores, develops, produces and markets crude oil, natural gas liquids (NGLs) and natural gas. Cenovus Energy produces n …
  • SGL Carbon SE (SGL):企業の財務・戦略的SWOT分析
    SGL Carbon SE (SGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Ypsomed Holding AG (YPSN):企業の製品パイプライン分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company that designs, develops and manufactures injection and infusion systems for self-medication and offers related services. It offers autoinjectors, dual chamber pens, and pen injectors. The company also offers services ranging from design …
  • Galera Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …
  • VAALCO Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    VAALCO Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary VAALCO Energy, Inc. (VAALCO) is an upstream oil and gas company. It acquires, explores, develops and produces crude oil and natural gas from assets. The company conducts the exploration activities …
  • Phillips 66 Co (PSX)-石油・ガス分野:企業M&A・提携分析
    Summary Phillips 66 Company (Phillips 66) is a diversified energy manufacturing and logistics company. It gathers, processes, transports and markets natural gas and petroleum products such as gasoline, diesel, aviation fuel and lubricants, and transports, fractionates and markets natural gas liquids …
  • New Sports Group Limited:企業のM&A・事業提携・投資動向
    New Sports Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Sports Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Booster Juice Ltd:企業の戦略・SWOT・財務情報
    Booster Juice Ltd - Strategy, SWOT and Corporate Finance Report Summary Booster Juice Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Doosan Infracore Co Ltd (042670):企業の財務・戦略的SWOT分析
    Doosan Infracore Co Ltd (042670) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sino Hotels (Holdings) Limited:企業の戦略・SWOT・財務分析
    Sino Hotels (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Sino Hotels (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Infineon Technologies AG (IFX):企業の財務・戦略的SWOT分析
    Infineon Technologies AG (IFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Gulf Oil Limited Partnership:企業の戦略的SWOT分析
    Gulf Oil Limited Partnership - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Recordati Rare Diseases Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Recordati Rare Diseases Inc (RRD), a subsidiary of Recordati SpA is a biopharmaceutical company that discovers and develops orphan drugs and biologics. The company’s products comprise chemet, neoprofen, panhematin, desoxyn, mustargen, carbaglu, cosmegen, peganone and tranxene, among others. …
  • Sumitomo Corp (8053):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumitomo Corp (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resources and …
  • Sebia SA:製品パイプライン分析
    Summary Sebia SA (Sebia) is a medical device company that designs, manufactures, commercializes, and exports electrophoresis tests and analyzers for diagnosis of cancer. The company's electrophoresis program offer automated system for capillary electrophoresis, gel electrophoresis and electrophoresi …
  • Ardelyx Inc (ARDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • Ramsay Health Care Ltd (RHC):企業の財務・戦略的SWOT分析
    Ramsay Health Care Ltd (RHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Verastem Inc (VSTM):企業の財務・戦略的SWOT分析
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Donaldson Company, Inc.:戦略・SWOT・企業財務分析
    Donaldson Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Donaldson Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Innovation Pharmaceuticals Inc (IPIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆